2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕，「肿瘤资讯」整理了会上将进行报告的妇瘤相关口头报告研究，供您参考。
Proffered Paper session
评价奥拉帕利 + 贝伐珠单抗维持治疗新诊断晚期卵巢癌患者的 III 期 PAOLA-1/ENGOT-ov25 试验的最终总生存期结果
摘要号：LBA29
原标题：Final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
报告专家：Isabelle L. Ray-Coquard (Lyon, France)
III 期 ATALANTE/ov29 试验：在含铂化疗联合贝伐珠单抗治疗对铂敏感复发上皮性卵巢癌患者中，比较阿替利珠单抗和安慰剂的疗效
摘要号：LBA30
原标题：Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
报告专家：Jean Emmanuel Kurtz (Strasbourg, France)
随机III期GOTIC-002 LUFT试验：替加氟-尿嘧啶维持化疗与观察后同步放化疗在局部晚期宫颈癌的比较
摘要号：LBA31
原标题：Randomized phase 3 trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial
报告专家：Keiichi Fujiwara (Saitama, Japan)
在SOLO1/GOG-3004试验中接受奥拉帕利维持治疗的新诊断BRCA突变晚期卵巢癌患者7年随访的总生存期
摘要号：517O
原标题：Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
报告专家：Paul DiSilvestro (Providence, United States of America)
ARIEL4的总生存期结果:一项评估rucaparib vs化疗治疗晚期、复发有害BRCA1/2突变卵巢癌患者的III期研究
摘要号：518O
原标题：Overall survival results from ARIEL4: a phase 3 study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
报告专家：Amit M. Oza (Toronto, Ontario, Canada)
Mini Oral session
GX-188E（一种治疗性 DNA 疫苗）联合帕博利珠单抗治疗 HPV 16 和/或 18 阳性晚期宫颈癌（II 期）的疗效和安全性：对 PD-L1 阳性和阴性患者均安全有效
摘要号：LBA32
原标题：Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (Phase II): Safe and effective in both PD-L1 positive and negative
报告专家：Sungjong Lee (Seoul, Korea, Republic of)
III期EMPOWER-Cervical 1/GOG-3016/ ENGOT-cx9临床试验中cemiplimab治疗复发或转移性宫颈癌:长期生存分析
摘要号：519MO
原标题：Phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
报告专家：Ana Oaknin (Barcelona, Spain)
CheckMate 358 研究：纳武利尤单抗±伊匹木单抗治疗复发性/转移性宫颈癌患者的安全性和疗效
摘要号：520MO
原标题：Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in CheckMate 358
报告专家：Ana Oaknin (Barcelona, Spain)
帕博利珠单抗单药治疗晚期透明细胞妇瘤的疗效：II期 PEACOCC 试验
摘要号：521MO
原标题：Efficacy of Pembrolizumab Monotherapy (PM) for Advanced Clear Cell Gynaecological Cancer (CCGC): Phase II PEACOCC Trial
报告专家：Rebecca Kristeleit (London, United Kingdom)
信迪利单抗联合贝伐珠单抗治疗复发性/持续性卵巢透明细胞癌的初步结果：一项多中心、单臂、II期临床试验
摘要号：522MO
原标题：Preliminary results of Sintilimab (Sin)+Bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial
报告专家：Xingyu Liu (Wuhan, China)
Ubamatamab（REGN4018，MUC16xCD3双特异性抗体）单药治疗复发性卵巢癌患者：I期剂量递增分析
摘要号：523MO
原标题：Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase 1 dose-escalation analysis
报告专家：Els Van Nieuwenhuysen (Leuven, Belgium)
糖皮质激素受体调制剂relacorilant联合白蛋白紫杉醇治疗卵巢癌的II期临床试验中糖皮质激素受体的表达和活性
摘要号：524MO
原标题：Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel
报告专家：Domenica Lorusso (Rome, Italy)
仑伐替尼 + 帕博利珠单抗 vs 医生选择治疗在晚期子宫内膜癌患者中的最新疗效和安全性: Study 309/KEYNOTE-775
摘要号：525MO
原标题：Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
报告专家：Vicky Makker (New York City, United States of America)
早期宫颈癌前哨淋巴结的病理评估：前瞻性SENTIX试验结果(CEEGOG-CX01;ENGOT-CX2)
摘要号：526MO
原标题：Pathological assessment of sentinel lymph node in early-stage cervical cancer. Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2).
报告专家：David Cibula (Prague, Czech Republic)
rucaparib维持治疗新诊断卵巢癌患者：根据III期ATHENA-MONO研究中的疾病风险亚组确定获益
摘要号：527MO
原标题：Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study
报告专家：Rebecca Kristeleit (London, United Kingdom)
复发性卵巢癌患者寡转移进展局部治疗后重新引入或继续使用PARP抑制剂是否有意义?
摘要号：528MO
原标题：Is reintroduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
报告专家：Gauduchon Thibault (Lyon, France)
奥拉帕利+度伐利尤单抗联合或不联合贝伐珠单抗的II期研究(MEDIOLA)：对非胚系BRCA突变铂敏感复发卵巢癌患者总生存期的最终分析
摘要号：529MO
原标题：Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
报告专家：Susana Banerjee (London, United Kingdom)
排版编辑：肿瘤资讯-Paine
苏公网安备32059002004080号
